CAS: 13602-11-4; Methyl 6-Methylpyridine-2-Carboxylate

相似化合物

1122-71-0 1122-72-1 934-60-1

上下游产品

CAS号67-56-1 甲醇 | CAS号934-60-1 6-甲基-2-吡啶甲酸 | CAS号18107-18-1 (三甲硅烷)重氮甲烷 | CAS号5315-25-3 2-溴-6-甲基吡啶 | CAS号201230-82-2 carbon monoxide | CAS号126125-54-0 6-甲基吡啶甲酰氯 | CAS号186581-53-3 重氮甲烷 | CAS号39977-44-1 6-羟甲基吡啶-2-羧酸甲酯 | CAS号3099-29-4 2-氯甲基-6-甲基吡啶 | CAS号79651-64-2 2-氨基-6-吡啶甲醇 | CAS号934-60-1 6-甲基-2-吡啶甲酸 | CAS号7170-36-7 2,6-吡啶二羧酸单甲酯 | CAS号68470-59-7 2-溴甲基-6-甲基吡啶 | CAS号69950-65-8 6-甲酰基-2-吡啶甲酸甲酯 | CAS号13287-64-4 (6-甲基吡啶-2-基)甲基乙酸酯 | CAS号1122-71-0 6-甲基-2-吡啶基甲醇 | CAS号146462-25-1 2-溴甲基-6-吡啶甲酸甲酯

2-溴-6-甲基吡啶置于正丁基锂,四丁基二氟三苯硅酸铵体系中,用 氘代四氢呋喃,乙醚,正己烷 用作溶剂,-78.0~20.0 °C,100.0 Kpa 条件下,反应 37.0H,反应生成6-甲基-2-吡啶甲酸甲酯
参考文献:氟介导的有机硅烷和卤化物衍生物将二氧化碳转化为酯
标题:氟介导的有机硅烷和卤化物衍生物将二氧化碳转化为酯
摘要:在无金属条件下,Co 2一步转化为杂芳族酯.使用氟阴离子作为c-Si键活化的促进剂,吡啶基,呋喃基和噻吩基有机硅烷在亲电试剂存在下成功被co 2羧化.根据实验和计算结果阐明了这种空前反应的机理,该结果表明co 2在吡啶基硅烷的c-Si键活化中具有独特的催化作用.该方法适用于18种不同的酯,并且首次使co 2可以掺入聚酯材料中.
Doi:10.1002/chem.201505092

专利信息

专利号:US-9475814-B2
优先权日:2011-10-03
标题:Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
发明人：HOVEYDA HAMID R; DUTHEUIL GUILLAUME; FRASER GRAEME L; ROY MARIE-ODILE; EL BOUSMAQUI MOHAMED; BATT FREDERIC
权利人:EUROSCREEN SA
摘要:The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

专利号:US-2017240485-A1
优先权日:2014-10-21
标 题:Synthesis of Esters by Functionalisation of CO2

专利号:WO-2023280237-A1
优先权日:2021-07-07
标题 :Synthesis and application of phosphatase degrader

专利号:MX-2014004057-A
优先权日:2011-10-03
标题:N-ACIL-5,6,7, (8-REPLACED) -TETRAHYDRO- [1,2,4] TRIAZOLO [4,3-A] PIRA QUIRAL ZINAS, NOVEDOSAS, AS SELECTIVE ANTAGONISTS OF NK-3 RECEPTOR; PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN DISORDERS MEDIATED BY NK-3 RECEPTOR AND ITS CHIRAL SYNTHESIS.